$INDP News

Indaptus Therapeutics Q1 EPS $(0.23) Beats $(1.87) Estimate

Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

Indaptus Entered Into $6M Securities Purchase Agreement With Investor David Lazar

Indaptus Entered Into $6M Securities Purchase Agreement With Investor David Lazar

What Does the Market Think About Indaptus Therapeutics Inc?

Market-Moving News for December 24th

Indaptus Therapeutics Appoints David Lazar As The Co-Chief Executive Officer

Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit

Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Indaptus Therapeutics Q3 EPS $(2.98) Beats $(4.17) Estimate

Indaptus Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 109.76%

Indaptus Therapeutics Shares Resume Trade

Indaptus Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 77.13%

Indaptus Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 50.91%

Indaptus Therapeutics shares are trading lower. The company announced recent updates for its ongoing INDP-D101 clinical trial.

Indaptus Therapeutics Provides Clinical Update

Indaptus Reports Partial Response From Decoy20 Monotherapy In Urothelial Cancer; Combo With PD-1 Inhibitor Shows Favorable Safety

Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference

Indaptus Therapeutics: Files For Mixed Shelf Offering Of Up To $200M

Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update